

Top Medications for Breast Cancer Patients

The FREQ Procedure

description	Frequency
1 ML Epoetin Alfa 4000 UNT/ML Injection [Epogen]	4059
1 ML medroxyPROGESTERone acetate 150 MG/ML Injection	93
1 ML medroxyprogesterone acetate 150 MG/ML Injection	242
168 HR Ethinyl Estradiol 0.00146 MG/HR / norelgestromin	72
24 HR Nicotine 0.292 MG/HR Transdermal System	3
24 HR metoprolol succinate 100 MG Extended Release Oral	19
Acetaminophen 160 MG Chewable Tablet	20
Acetaminophen 325 MG Oral Tablet	1147
Acetaminophen/Hydrocodone	2
Allopurinol 100 MG Oral Tablet	3
Alteplase 100 MG Injection	55
Amoxicillin 250 MG Oral Capsule	11
Amoxicillin 500 MG Oral Tablet	68
Astemizole 10 MG Oral Tablet	11
Camila 28 Day Pack	257
Carbamazepine[Tegretol]	14
Chlorpheniramine Maleate 4 MG Oral Tablet	5
Cisplatin 50 MG Injection	5
Clopidogrel 75 MG Oral Tablet	1314
Colchicine 0.6 MG Oral Tablet	1
Diazepam 5 MG Oral Tablet	10
EPINEPHrine (generic for Adrenaclick) 0.3 MG per 0.3 ML	45
EPINEPHrine 1 MG per 1 ML Injection	13
Errin 28 Day Pack	225
Estrostep Fe 28 Day Pack	19
FLUoxetine 20 MG (as FLUoxetine HCl 22.4 MG) Oral Capsu	5
Fexofenadine hydrochloride 60 MG Oral Tablet	5
Furosemide 40 MG Oral Tablet	19
HYDROcodone bitartrate 5 MG / acetaminophen 300 MG Oral	27
HYDROcodone bitartrate 7.5 MG / acetaminophen 325 MG Or	66
HYDROcodone bitartrate 7.5 MG / acetaminophen 750 MG Or	1
Hydrochlorothiazide 25 MG Oral Tablet	11150
Hydrocortisone 10 MG/ML Topical Cream	54
Ibuprofen 100 MG Oral Tablet	24
Ibuprofen 200 MG Oral Tablet	321
Jolivet 28 Day Pack	281
Kyleena 19.5 MG Intrauterine System	37
Leucovorin 100 MG Injection	32
Levora 0.15/30 28 Day Pack	160
Levothyroxine Sodium 0.075 MG Oral Tablet	44
Liletta 52 MG Intrauterine System	47
Loratadine 10 MG Oral Tablet	7
Methotrexate 2.5 MG Oral Tablet	5
Mirena 52 MG Intrauterine System	236
NDA020503 200 ACTUAT Albuterol 0.09 MG/ACTUAT Metered D	4340
Frequency Missing = 152	

description	Frequency
NITROFURANTOIN, MACROCRYSTALS 50 MG Oral Capsule	24
Naproxen 500 MG Oral Tablet	25
Naproxen sodium 220 MG Oral Tablet	621
Natazia 28 Day Pack	173
NuvaRing 0.12/0.015 MG per 24HR 21 Day Vaginal Ring	101
Ortho Tri-Cyclen 28 Day Pack	19
Penicillin V Potassium 250 MG Oral Tablet	21
Penicillin V Potassium 500 MG Oral Tablet	143
Seasonique 91 Day Pack	183
Simvastatin 10 MG Oral Tablet	6230
Simvastatin 20 MG Oral Tablet	1373
Sodium Chloride 9 MG/ML Injectable Solution	12
Tenoretic-50 50 MG / 25 MG Oral Tablet	8371
Terfenadine 60 MG Oral Tablet	7
Trinessa 28 Day Pack	197
Verapamil Hydrochloride 40 MG	1406
Vitamin B 12 5 MG/ML Injectable Solution	146
Warfarin Sodium 5 MG Oral Tablet	1420
Yaz 28 Day Pack	179
acetaminophen 650 MG / dextromethorphan HBr 30 MG / dox	239
alendronate sodium 10 MG Oral Tablet	148
amLODIPine besylate 5 MG Oral Tablet	1326
amiodarone HCl 150 MG in 3 ML Prefilled Syringe	13
amoxicillin 250 MG / clavulanate potassium 125 MG Oral	409
atomoxetine 100 MG Oral Capsule	1
atorvastatin calcium 80 MG Oral Tablet	1
atropine sulfate 1 MG in 1 ML Injection	13
cefuroxime axetil 250 MG Oral Tablet	19
cetirizine HCl 5 MG Oral Tablet	2
cetirizine hydrochloride 10 MG Oral Tablet	2
chlorpheniramine maleate 2 MG in 1 mL Oral Solution	36
clonazepam 0.25 MG Oral Tablet	7
cycloSPORINE, modified 100 MG Oral Capsule	5
digoxin 125 MCG Oral Tablet	1420
diphenhydramine HCl 25 MG Oral Tablet	76
donepezil HCl 10 MG / memantine HCl 28 MG 24HR Extended	39
duloxetine 20 MG Delayed Release Oral Capsule	18
etonogestrel 68 MG Subdermal Drug Implant	336
ferrous sulfate 325 MG Oral Tablet	119
fexofenadine HCl 30 MG Oral Tablet	8
fluticasone propionate 44 MCG/INHAL Metered Dose Inhale	4340
fluticasone propionate/salmeterol 250/50 MCG/INHAL Dry	1083
furosemide 100 MG in 10 ML Injection	4
galantamine HBr 4 MG Oral Tablet	53
heparin sodium, porcine 5000 UNT in 1 ML Injection	12
hydrochlorothiazide 12.5 MG Oral Tablet	3983
insulin human, isophane 70 UNT/ML / Regular Insulin, Hu	5960
loratadine 5 MG 24HR Chewable Tablet	10
Frequency Missing = 152	

description	Frequency
memantine HCl 2 MG in 1 mL Oral Solution	3
meperidine HCl 50 MG Oral Tablet	78
metFORMIN HCl 500 MG 24 HR Extended Release Oral Tablet	6471
methylphenidate HCl 20 MG Oral Tablet	2
milnacipran HCl 100 MG Oral Tablet	15
morphine sulfate 5 MG in 1 ML Injection	12
nitrofurantoin 25 MG in 5 mL Oral Suspension	167
nitroglycerin 400 MCG/ACTUAT Mucosal Spray	1542
olmesartan medoxomil 20 MG / amLODIPine 5 MG / hydrochl	6945
ondansetron 4 MG in 2 ML Injection	12
oxaliplatin 50 MG in 10 ML Injection	32
oxyCODONE 5 MG / acetaminophen 325 MG Oral Tablet	102
oxyCODONE HCl 15 MG 12 HR Extended Release Oral Tablet,	24
phenazopyridine HCl 100 MG Oral Tablet	167
piperacillin / tazobactam 4.5 GM Injection	12
predniSONE 5 MG Oral Tablet	7
pregabalin 100 MG Oral Capsule	21
sertraline HCl 100 MG Oral Tablet	2
Frequency Missing = 152	

Top Procedures for Breast Cancer Patients

The FREQ Procedure

description	Frequency
Admission to burn unit	7
Admission to long stay hospital	7
Admission to neurosurgical department	2
Admission to orthopedic department	71
Admission to trauma surgery departmen	2
Allergy screening test	27
Alpha-fetoprotein test - antenatal (p	515
Amputation of right leg	1
Ankle X-ray	39
Antenatal RhD antibody screening	71
Appendectomy	9
Asthma screening	5
Augmentation of labor	48
Auscultation of the fetal heart	4645
Bilateral tubal ligation	31
Biopsy of breast (procedure)	1456
Biopsy of colon	22
Blood group typing (procedure)	513
Bone density scan (procedure)	2295
Bone immobilization	204
Brachytherapy of breast (procedure)	77
Brief general examination (procedure)	130
Catheter ablation of tissue of heart	292
Cesarean section	65

description	Frequency
Chemotherapy (procedure)	6317
Chest X-ray	33
Childbirth	428
Chlamydia antigen test	513
Clavicle X-ray	54
Cognitive and behavioral therapy	21
Colonoscopy	1813
Combined chemotherapy and radiation t	129
Computed tomography of chest and abdo	3
Coronary artery bypass grafting	1
Counseling for termination of pregnan	72
Cytopathology procedure, preparation	4505
Depression screening	867
Depression screening using Patient He	2
Detection of chromosomal aneuploidy i	520
Digital examination of rectum	9
Echocardiography (procedure)	69
Electrical cardioversion	1148
Electrocardiographic procedure	12
Electroencephalogram (procedure)	3
Epidural anesthesia	102
Episiotomy	138
Evaluation of uterine fundal height	4645
Excision of axillary lymph node (proc	292
Excision of breast tissue (procedure)	567
Excision of fallopian tube and surgic	12
Excision of sentinel lymph node (proc	242
Extraction of wisdom tooth	27
Fetal anatomy study	515
Gonorrhea infection titer test (proce	513
Hearing examination (procedure)	40
Hemogram, automated, with red blood c	1029
Hepatitis B Surface Antigen Measureme	513
Hepatitis C antibody, confirmatory te	513
High resolution computed tomography o	40
Human epidermal growth factor recepto	2912
Human immunodeficiency virus antigen	513
Induced termination of pregnancy	72
Information gathering (procedure)	105
Injection of epinephrine (procedure)	7
Injection of tetanus antitoxin	69
Insertion of biventricular implantabl	13
Insertion of intrauterine contracepti	427
Insertion of subcutaneous contracepti	460
Instrumental delivery	36
Interstitial brachytherapy (procedure	35
Intracavitary brachytherapy (procedur	42
Intramuscular injection	3977
Intravenous blood transfusion of pack	10

description	Frequency
Intravenous injection (procedure)	103
Intubation	12
Knee X-ray	50
Laparoscopic cholecystectomy (procedu	10
Lung volume reduction surgery (proced	5
Magnetic resonance imaging for measur	3
Magnetic resonance imaging of breast	353
Mammogram - symptomatic (procedure)	578
Mammography (procedure)	6997
Manual pelvic examination (procedure)	3992
Measurement of Varicella-zoster virus	513
Measurement of respiratory function (469
Medical induction of labor	94
Medication Reconciliation (procedure)	9319
Megavoltage radiation therapy using p	26493
Mental health screening (procedure)	1
Methotrexate injection into tubal pre	17
Nasal sinus endoscopy (procedure)	18
Open Removal of Gall Bladder	4
Partial mastectomy (procedure)	824
Partial resection of colon	24
Passive immunization (procedure)	209
Pelvis X-ray	17
Percutaneous coronary intervention	1
Percutaneous mechanical thrombectomy	55
Peripheral blood smear interpretation	130
Physical exam following abortion	71
Physical examination	256
Physical examination following birth	540
Physical examination of mother	513
Plain chest X-ray	5
Plain chest X-ray (procedure)	52
Pregnancy termination care	71
Premature birth of newborn	39
Pulmonary rehabilitation (regime/ther	211
Radiation oncology AND/OR radiotherap	2825
Radiography of wrist (procedure)	69
Rectal polypectomy	221
Referral to hypertension clinic	1
Removal of intrauterine device	241
Removal of subcutaneous contraceptive	344
Renal dialysis (procedure)	4060
Replacement of contraceptive intraute	302
Review of systems (procedure)	130
Rubella screening	513
Screening for occult blood in feces (185
Screening mammography (procedure)	878
Sentinel lymph node biopsy (procedure	242
Skin test for tuberculosis, Tine test	513

description	Frequency
Spirometry (procedure)	530
Spontaneous breech delivery	2
Sputum examination (procedure)	196
Sputum microscopy (procedure)	2
Standard pregnancy test	828
Streptococcus pneumoniae group B anti	484
Subcutaneous immunotherapy	685
Suicide risk assessment (procedure)	3
Surgical manipulation of joint of kne	40
Surgical manipulation of shoulder joi	1
Suture open wound	313
Syphilis infectious titer test (proce	513
Thoracentesis (procedure)	1
Throat culture (procedure)	327
Transplant of lung (procedure)	3
Transthoracic echocardiography	5
Transthoracic three dimensional ultra	42
Ultrasonography of abdomen, right upp	12
Ultrasonography of bilateral breasts	1103
Ultrasound scan for fetal viability	828
Upper arm X-ray	63
Urine culture	513
Urine protein test	513
Urine screening for glucose	516
Urine screening test for diabetes	513
Vaccination for diphtheria, pertussis	516

Kaplan-Meier Survival Curve for Breast Cancer Patients

The LIFETEST Procedure


Product-Limit Survival Estimates					
observed_duration		Survival	Failure	Survival Standard Error	Number Failed Number Left
0		1.0000	0	0	0 11
10484206	*	.	.	.	0 10
67607231	*	.	.	.	0 9
79733030	*	.	.	.	0 8
1.0957E8	*	.	.	.	0 7
1.4932E8	*	.	.	.	0 6
1.6206E8	*	.	.	.	0 5
2.4733E8	*	.	.	.	0 4
2.4911E8	*	.	.	.	0 3
3.0697E8	*	.	.	.	0 2
3.467E8	*	.	.	.	0 1
5.8855E8	*	.	.	.	0 0

Note: The marked survival times are censored observations.

Summary Statistics for Time Variable observed_duration

Quartile Estimates				
Percent	Point Estimate	95% Confidence Interval		
		Transform	[Lower	Upper)
75	.	LOGLOG	.	.
50	.	LOGLOG	.	.
25	.	LOGLOG	.	.

Mean	Standard Error
.	.



Summary of the Number of Censored and Uncensored Values			
Total	Failed	Censored	Percent Censored
11	0	11	100.00

Note: 1845 observations with invalid time or censoring values were deleted.

Kaplan-Meier Survival Curve for Breast Cancer Patients

The MEANS Procedure

Analysis Variable : observed_duration				
N	Mean	Std Dev	Minimum	Maximum

Analysis Variable : observed_duration				
N	Mean	Std Dev	Minimum	Maximum
1856	4447.74	4163.42	1733.00	30554.00

Kaplan-Meier Survival Curve for Breast Cancer Patients

The FREQ Procedure

event_observed	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0	1856	100.00	1856	100.00

Kaplan-Meier Survival Curve for Breast Cancer Patients

The FREQ Procedure

event_observed	Frequency	Percent	Cumulative Frequency	Cumulative Percent
0	1504	81.03	1504	81.03
1	352	18.97	1856	100.00

Kaplan-Meier Survival Curve for Breast Cancer Patients


The MEANS Procedure

Analysis Variable : observed_duration				
N	Mean	Std Dev	Minimum	Maximum
1856	3598.34	4041.73	1.0000000	30554.00

Kaplan-Meier Survival Curve for Breast Cancer Patients

The LIFETEST Procedure

Product-Limit Survival Estimates						
observed_duration		Survival	Failure	Survival Standard Error	Number Failed	Number Left
0.0		1.0000	0	0	0	1856
1.0		.	.	.	1	1855
1.0		0.9989	0.00108	0.000762	2	1854
2.0		.	.	.	3	1853
2.0		0.9978	0.00216	0.00108	4	1852
3.0		0.9973	0.00269	0.00120	5	1851
4.0		.	.	.	6	1850
4.0		.	.	.	7	1849
4.0		0.9957	0.00431	0.00152	8	1848
5.0		.	.	.	9	1847
5.0		.	.	.	10	1846
5.0		0.9941	0.00593	0.00178	11	1845
6.0		.	.	.	12	1844
6.0		0.9930	0.00700	0.00194	13	1843



Summary of the Number of Censored and Uncensored Values			
Total	Failed	Censored	Percent Censored
1856	352	1504	81.03

Kaplan-Meier Survival Curve for Breast Cancer Patients

The LIFETEST Procedure

Product-Limit Survival Estimates					
observed_duration	Survival	Failure	Survival Standard Error	Number Failed	Number Left
0.0	1.0000	0	0	0	1856
1.0	.	.	.	1	1855
1.0	0.9989	0.00108	0.000762	2	1854
2.0	.	.	.	3	1853
2.0	0.9978	0.00216	0.00108	4	1852
3.0	0.9973	0.00269	0.00120	5	1851
4.0	.	.	.	6	1850
4.0	.	.	.	7	1849
4.0	0.9957	0.00431	0.00152	8	1848
5.0	.	.	.	9	1847
5.0	.	.	.	10	1846
5.0	0.9941	0.00593	0.00178	11	1845
6.0	.	.	.	12	1844

Product-Limit Survival Estimates					
observed_duration	Survival	Failure	Survival Standard Error	Number Failed	Number Left
6.0	0.9930	0.00700	0.00194	13	1843
7.0	.	.	.	14	1842
7.0	.	.	.	15	1841
7.0	0.9914	0.00862	0.00215	16	1840
9.0	0.9908	0.00916	0.00221	17	1839
10.0	.	.	.	18	1838
10.0	.	.	.	19	1837
10.0	.	.	.	20	1836
10.0	0.9887	0.0113	0.00246	21	1835
11.0	.	.	.	22	1834
11.0	.	.	.	23	1833
11.0	0.9871	0.0129	0.00262	24	1832
12.0	.	.	.	25	1831
12.0	0.9860	0.0140	0.00273	26	1830
13.0	0.9855	0.0145	0.00278	27	1829
14.0	.	.	.	28	1828
14.0	.	.	.	29	1827
14.0	0.9838	0.0162	0.00293	30	1826
15.0	0.9833	0.0167	0.00297	31	1825
16.0	.	.	.	32	1824
16.0	0.9822	0.0178	0.00307	33	1823
17.0	0.9817	0.0183	0.00311	34	1822
18.0	.	.	.	35	1821
18.0	.	.	.	36	1820
18.0	.	.	.	37	1819
18.0	.	.	.	38	1818
18.0	.	.	.	39	1817
18.0	0.9784	0.0216	0.00337	40	1816
19.0	.	.	.	41	1815
19.0	0.9774	0.0226	0.00345	42	1814
20.0	.	.	.	43	1813
20.0	0.9763	0.0237	0.00353	44	1812
21.0	0.9758	0.0242	0.00357	45	1811
25.0	.	.	.	46	1810
25.0	.	.	.	47	1809
25.0	0.9741	0.0259	0.00368	48	1808
26.0	.	.	.	49	1807
26.0	0.9731	0.0269	0.00376	50	1806
27.0	.	.	.	51	1805
27.0	0.9720	0.0280	0.00383	52	1804
28.0	.	.	.	53	1803
28.0	.	.	.	54	1802
28.0	0.9704	0.0296	0.00394	55	1801
29.0	.	.	.	56	1800
29.0	.	.	.	57	1799
29.0	.	.	.	58	1798
29.0	.	.	.	59	1797
29.0	0.9677	0.0323	0.00411	60	1796

Product-Limit Survival Estimates					
observed_duration		Survival	Failure	Survival Standard Error	Number Failed Number Left
30.0		.	.	.	61 1795
30.0		0.9666	0.0334	0.00417	62 1794
31.0		0.9661	0.0339	0.00420	63 1793
32.0		.	.	.	64 1792
32.0		0.9650	0.0350	0.00427	65 1791
33.0		.	.	.	66 1790
33.0		0.9639	0.0361	0.00433	67 1789
34.0		0.9634	0.0366	0.00436	68 1788
35.0		.	.	.	69 1787
35.0		.	.	.	70 1786
35.0		.	.	.	71 1785
35.0		.	.	.	72 1784
35.0		0.9607	0.0393	0.00451	73 1783
37.0		.	.	.	74 1782
37.0		.	.	.	75 1781
37.0		0.9591	0.0409	0.00460	76 1780
38.0		.	.	.	77 1779
38.0		0.9580	0.0420	0.00466	78 1778
39.0		0.9574	0.0426	0.00469	79 1777
40.0		0.9569	0.0431	0.00471	80 1776
42.0		.	.	.	81 1775
42.0		0.9558	0.0442	0.00477	82 1774
43.0		.	.	.	83 1773
43.0		0.9547	0.0453	0.00483	84 1772
44.0		.	.	.	85 1771
44.0		.	.	.	86 1770
44.0		0.9531	0.0469	0.00491	87 1769
45.0		.	.	.	88 1768
45.0		0.9520	0.0480	0.00496	89 1767
46.0		0.9515	0.0485	0.00499	90 1766
47.0		0.9510	0.0490	0.00501	91 1765
48.0		.	.	.	92 1764
48.0		.	.	.	93 1763
48.0		.	.	.	94 1762
48.0		0.9488	0.0512	0.00512	95 1761
49.0		0.9483	0.0517	0.00514	96 1760
50.0		.	.	.	97 1759
50.0		0.9472	0.0528	0.00519	98 1758
51.0		.	.	.	99 1757
51.0		.	.	.	100 1756
51.0		.	.	.	101 1755
51.0		0.9450	0.0550	0.00529	102 1754
52.0		.	.	.	103 1753
52.0		0.9440	0.0560	0.00534	104 1752
53.0		.	.	.	105 1751
53.0		0.9429	0.0571	0.00539	106 1750
54.0		0.9423	0.0577	0.00541	107 1749
55.0		0.9418	0.0582	0.00543	108 1748

Product-Limit Survival Estimates					
observed_duration		Survival	Failure	Survival Standard Error	Number Failed Number Left
56.0		.	.	.	109 1747
56.0		0.9407	0.0593	0.00548	110 1746
57.0		.	.	.	111 1745
57.0		.	.	.	112 1744
57.0		0.9391	0.0609	0.00555	113 1743
58.0		.	.	.	114 1742
58.0		0.9380	0.0620	0.00560	115 1741
60.0		.	.	.	116 1740
60.0		.	.	.	117 1739
60.0		0.9364	0.0636	0.00566	118 1738
61.0		0.9359	0.0641	0.00569	119 1737
62.0		.	.	.	120 1736
62.0		0.9348	0.0652	0.00573	121 1735
64.0		.	.	.	122 1734
64.0		.	.	.	123 1733
64.0		0.9332	0.0668	0.00580	124 1732
66.0		.	.	.	125 1731
66.0		.	.	.	126 1730
66.0		.	.	.	127 1729
66.0		0.9310	0.0690	0.00588	128 1728
67.0		.	.	.	129 1727
67.0		.	.	.	130 1726
67.0		0.9294	0.0706	0.00595	131 1725
68.0		.	.	.	132 1724
68.0		0.9283	0.0717	0.00599	133 1723
69.0		0.9278	0.0722	0.00601	134 1722
70.0		0.9273	0.0727	0.00603	135 1721
71.0		.	.	.	136 1720
71.0		0.9262	0.0738	0.00607	137 1719
72.0		.	.	.	138 1718
72.0		0.9251	0.0749	0.00611	139 1717
73.0		0.9246	0.0754	0.00613	140 1716
74.0		.	.	.	141 1715
74.0		.	.	.	142 1714
74.0		.	.	.	143 1713
74.0		0.9224	0.0776	0.00621	144 1712
75.0		.	.	.	145 1711
75.0		0.9213	0.0787	0.00625	146 1710
76.0		0.9208	0.0792	0.00627	147 1709
77.0		.	.	.	148 1708
77.0		.	.	.	149 1707
77.0		0.9192	0.0808	0.00633	150 1706
78.0		0.9186	0.0814	0.00635	151 1705
80.0		0.9181	0.0819	0.00636	152 1704
81.0		0.9176	0.0824	0.00638	153 1703
83.0		.	.	.	154 1702
83.0		0.9165	0.0835	0.00642	155 1701
84.0		0.9159	0.0841	0.00644	156 1700

Product-Limit Survival Estimates					
observed_duration		Survival	Failure	Survival Standard Error	Number Failed Number Left
85.0		.	.	.	157 1699
85.0		.	.	.	158 1698
85.0		0.9143	0.0857	0.00650	159 1697
86.0		.	.	.	160 1696
86.0		0.9133	0.0867	0.00653	161 1695
87.0		.	.	.	162 1694
87.0		0.9122	0.0878	0.00657	163 1693
88.0		.	.	.	164 1692
88.0		.	.	.	165 1691
88.0		.	.	.	166 1690
88.0		0.9100	0.0900	0.00664	167 1689
90.0		.	.	.	168 1688
90.0		.	.	.	169 1687
90.0		0.9084	0.0916	0.00670	170 1686
91.0		.	.	.	171 1685
91.0		0.9073	0.0927	0.00673	172 1684
93.0		0.9068	0.0932	0.00675	173 1683
95.0		0.9063	0.0938	0.00677	174 1682
96.0		0.9057	0.0943	0.00678	175 1681
99.0		0.9052	0.0948	0.00680	176 1680
100.0		.	.	.	177 1679
100.0		.	.	.	178 1678
100.0		0.9036	0.0964	0.00685	179 1677
101.0		0.9030	0.0970	0.00687	180 1676
102.0		.	.	.	181 1675
102.0		.	.	.	182 1674
102.0		0.9014	0.0986	0.00692	183 1673
103.0		0.9009	0.0991	0.00694	184 1672
104.0		0.9003	0.0997	0.00695	185 1671
105.0		0.8998	0.1002	0.00697	186 1670
107.0		.	.	.	187 1669
107.0		0.8987	0.1013	0.00700	188 1668
108.0		0.8982	0.1018	0.00702	189 1667
109.0		.	.	.	190 1666
109.0		0.8971	0.1029	0.00705	191 1665
110.0		.	.	.	192 1664
110.0		0.8960	0.1040	0.00709	193 1663
111.0		0.8955	0.1045	0.00710	194 1662
112.0		.	.	.	195 1661
112.0		.	.	.	196 1660
112.0		0.8939	0.1061	0.00715	197 1659
113.0		.	.	.	198 1658
113.0		0.8928	0.1072	0.00718	199 1657
114.0		.	.	.	200 1656
114.0		.	.	.	201 1655
114.0		0.8912	0.1088	0.00723	202 1654
115.0		.	.	.	203 1653
115.0		0.8901	0.1099	0.00726	204 1652

Product-Limit Survival Estimates					
observed_duration		Survival	Failure	Survival Standard Error	Number Failed Number Left
116.0		.	.	.	205 1651
116.0		.	.	.	206 1650
116.0		0.8885	0.1115	0.00731	207 1649
117.0		.	.	.	208 1648
117.0		.	.	.	209 1647
117.0		0.8869	0.1131	0.00735	210 1646
118.0		.	.	.	211 1645
118.0		0.8858	0.1142	0.00738	212 1644
119.0		.	.	.	213 1643
119.0		0.8847	0.1153	0.00741	214 1642
120.0		.	.	.	215 1641
120.0		0.8836	0.1164	0.00744	216 1640
121.0		.	.	.	217 1639
121.0		0.8825	0.1175	0.00747	218 1638
122.0		0.8820	0.1180	0.00749	219 1637
123.0		.	.	.	220 1636
123.0		0.8809	0.1191	0.00752	221 1635
124.0		.	.	.	222 1634
124.0		.	.	.	223 1633
124.0		.	.	.	224 1632
124.0		0.8788	0.1212	0.00758	225 1631
125.0		0.8782	0.1218	0.00759	226 1630
126.0		.	.	.	227 1629
126.0		.	.	.	228 1628
126.0		.	.	.	229 1627
126.0		.	.	.	230 1626
126.0		.	.	.	231 1625
126.0		0.8750	0.1250	0.00768	232 1624
127.0		0.8745	0.1255	0.00769	233 1623
128.0		.	.	.	234 1622
128.0		0.8734	0.1266	0.00772	235 1621
129.0		.	.	.	236 1620
129.0		.	.	.	237 1619
129.0		0.8718	0.1282	0.00776	238 1618
131.0		.	.	.	239 1617
131.0		.	.	.	240 1616
131.0		0.8702	0.1298	0.00780	241 1615
132.0		.	.	.	242 1614
132.0		.	.	.	243 1613
132.0		0.8685	0.1315	0.00784	244 1612
133.0		0.8680	0.1320	0.00786	245 1611
135.0		0.8675	0.1325	0.00787	246 1610
136.0		0.8669	0.1331	0.00788	247 1609
137.0		.	.	.	248 1608
137.0		0.8658	0.1342	0.00791	249 1607
138.0		.	.	.	250 1606
138.0		0.8648	0.1352	0.00794	251 1605
140.0		.	.	.	252 1604

Product-Limit Survival Estimates					
observed_duration		Survival	Failure	Survival Standard Error	Number Failed Number Left
140.0		.	.	.	253 1603
140.0		0.8631	0.1369	0.00798	254 1602
141.0		.	.	.	255 1601
141.0		.	.	.	256 1600
141.0		.	.	.	257 1599
141.0		.	.	.	258 1598
141.0		0.8605	0.1395	0.00804	259 1597
142.0		.	.	.	260 1596
142.0		.	.	.	261 1595
142.0		.	.	.	262 1594
142.0		0.8583	0.1417	0.00810	263 1593
145.0		0.8578	0.1422	0.00811	264 1592
146.0		0.8572	0.1428	0.00812	265 1591
147.0		.	.	.	266 1590
147.0		0.8561	0.1439	0.00815	267 1589
149.0		.	.	.	268 1588
149.0		0.8551	0.1449	0.00817	269 1587
150.0		0.8545	0.1455	0.00818	270 1586
151.0		.	.	.	271 1585
151.0		0.8534	0.1466	0.00821	272 1584
152.0		.	.	.	273 1583
152.0		.	.	.	274 1582
152.0		.	.	.	275 1581
152.0		0.8513	0.1487	0.00826	276 1580
153.0		0.8508	0.1492	0.00827	277 1579
154.0		0.8502	0.1498	0.00828	278 1578
156.0		.	.	.	279 1577
156.0		.	.	.	280 1576
156.0		0.8486	0.1514	0.00832	281 1575
157.0		0.8481	0.1519	0.00833	282 1574
158.0		0.8475	0.1525	0.00834	283 1573
159.0		.	.	.	284 1572
159.0		.	.	.	285 1571
159.0		0.8459	0.1541	0.00838	286 1570
160.0		.	.	.	287 1569
160.0		.	.	.	288 1568
160.0		0.8443	0.1557	0.00842	289 1567
162.0		.	.	.	290 1566
162.0		.	.	.	291 1565
162.0		.	.	.	292 1564
162.0		.	.	.	293 1563
162.0		0.8416	0.1584	0.00848	294 1562
163.0		.	.	.	295 1561
163.0		0.8405	0.1595	0.00850	296 1560
165.0		.	.	.	297 1559
165.0		0.8394	0.1606	0.00852	298 1558
166.0		0.8389	0.1611	0.00853	299 1557
167.0		.	.	.	300 1556

Product-Limit Survival Estimates						
observed_duration		Survival	Failure	Survival Standard Error	Number Failed	Number Left
19838.0	*	.	.	.	352	19
19854.0	*	.	.	.	352	18
20443.0	*	.	.	.	352	17
20841.0	*	.	.	.	352	16
20852.0	*	.	.	.	352	15
21295.0	*	.	.	.	352	14
21515.0	*	.	.	.	352	13
21612.0	*	.	.	.	352	12
22686.0	*	.	.	.	352	11
23049.0	*	.	.	.	352	10
23424.0	*	.	.	.	352	9
23864.0	*	.	.	.	352	8
24525.0	*	.	.	.	352	7
24665.0	*	.	.	.	352	6
25010.0	*	.	.	.	352	5
25470.0	*	.	.	.	352	4
25618.0	*	.	.	.	352	3
26625.0	*	.	.	.	352	2
27295.0	*	.	.	.	352	1
30554.0	*	.	.	.	352	0


Note: The marked survival times are censored observations.

Summary Statistics for Time Variable observed_duration

Quartile Estimates				
Percent	Point Estimate	95% Confidence Interval		
		Transform	[Lower	Upper)
75	.	LOGLOG	.	.
50	.	LOGLOG	.	.
25	.	LOGLOG	.	.

Mean	Standard Error
179.6	1.1

Note: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.



Summary of the Number of Censored and Uncensored Values			
Total	Failed	Censored	Percent Censored
1856	352	1504	81.03

Kaplan-Meier Survival Curve for Breast Cancer Patients

The PHREG Procedure

Model Information	
Data Set	MYDATA.BREAST_SURVIVAL
Dependent Variable	observed_duration
Censoring Variable	event_observed
Censoring Value(s)	0
Ties Handling	BRESLOW

Number of Observations Read	1856
Number of Observations Used	1856

Class Level Information		
Class	Value	Design Variables
gender	female	1
	male	0

Summary of the Number of Event and Censored Values			
Total	Event	Censored	Percent Censored
1856	352	1504	81.03


Convergence Status
Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics		
Criterion	Without Covariates	With Covariates
-2 LOG L	5227.571	5225.831
AIC	5227.571	5229.831
SBC	5227.571	5237.558

Testing Global Null Hypothesis: BETA=0			
Test	Chi-Square	DF	Pr > ChiSq
Likelihood Ratio	1.7398	2	0.4190
Score	0.8992	2	0.6379
Wald	0.0583	2	0.9713

Type 3 Tests			
Effect	DF	Wald Chi-Square	Pr > ChiSq
gender	1	0.0017	0.9671
age_at_onset	1	0.0566	0.8120

Analysis of Maximum Likelihood Estimates								
Parameter		DF	Parameter Estimate	Standard Error	Chi-Square	Pr > ChiSq	Hazard Ratio	Label
gender	female	1	11.01083	267.09920	0.0017	0.9671	60526.39	gender female
age_at_onset		1	0.0008229	0.00346	0.0566	0.8120	1.001	



Kaplan-Meier Survival Curve for Breast Cancer Patients

The PHREG Procedure

Model Information	
Data Set	MYDATA.BREAST_SURVIVAL
Dependent Variable	observed_duration
Censoring Variable	event_observed
Censoring Value(s)	0
Ties Handling	BRESLOW

Number of Observations Read	1856
Number of Observations Used	1856

Summary of the Number of Event and Censored Values			
Total	Event	Censored	Percent Censored
1856	352	1504	81.03

Convergence Status
Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics		
Criterion	Without Covariates	With Covariates
-2 LOG L	5227.571	5227.525

Model Fit Statistics		
Criterion	Without Covariates	With Covariates
AIC	5227.571	5229.525
SBC	5227.571	5233.389

Testing Global Null Hypothesis: BETA=0			
Test	Chi-Square	DF	Pr > ChiSq
Likelihood Ratio	0.0451	1	0.8318
Score	0.0450	1	0.8321
Wald	0.0445	1	0.8329

Analysis of Maximum Likelihood Estimates						
Parameter	DF	Parameter Estimate	Standard Error	Chi-Square	Pr > ChiSq	Hazard Ratio
age_at_onset	1	0.0007306	0.00346	0.0445	0.8329	1.001

Hazard Ratios for age_at_onset			
Description	Point Estimate	95% Wald Confidence Limits	
age_at_onset Unit=1	1.001	0.994	1.008

Kaplan-Meier Survival Curve for Breast Cancer Patients

The PHREG Procedure

Model Information	
Data Set	MYDATA.BREAST_SURVIVAL
Dependent Variable	observed_duration
Censoring Variable	event_observed
Censoring Value(s)	0
Ties Handling	BRESLOW

Number of Observations Read	1856
Number of Observations Used	1856

Summary of the Number of Event and Censored Values			
Total	Event	Censored	Percent Censored
1856	352	1504	81.03

Convergence Status
Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics		
Criterion	Without Covariates	With Covariates
-2 LOG L	5227.571	5227.525
AIC	5227.571	5229.525
SBC	5227.571	5233.389

Testing Global Null Hypothesis: BETA=0			
Test	Chi-Square	DF	Pr > ChiSq

Testing Global Null Hypothesis: BETA=0			
Test	Chi-Square	DF	Pr > ChiSq
Likelihood Ratio	0.0451	1	0.8318
Score	0.0450	1	0.8321
Wald	0.0445	1	0.8329

Analysis of Maximum Likelihood Estimates						
Parameter	DF	Parameter Estimate	Standard Error	Chi-Square	Pr > ChiSq	Hazard Ratio
age_at_onset	1	0.0007306	0.00346	0.0445	0.8329	1.001